Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

被引：0

作者：

Wiendl, H. ^{[1
]}

De Stefano, N. ^{[2
]}

Barkhof, F. ^{[3
]}

Montalban, X. ^{[4
]}

Achiron, A. ^{[5
]}

Derfuss, T. ^{[6
]}

Chan, A. ^{[7
]}

Hodgkinson, S. ^{[8
]}

Prat, A. ^{[9
]}

Leocani, L. ^{[10
]}

Schmierer, K. ^{[11
]}

Sellebjerg, F. ^{[12
]}

Vermersch, P. ^{[13
]}

Jin, H. ^{[14
]}

Jaervinen, E. ^{[14
]}

Chudecka, A. ^{[15
]}

Gardner, L. ^{[16
]}

机构：

[1] Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany

[2] Univ Siena, Dept Med Surg & Neurosci, Siena, Italy

[3] Vrije Univ Amsterdam, Dept Radiol, Med Ctr, Amsterdam, Netherlands

[4] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[5] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel

[6] Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[7] Bern Univ, Univ Hosp Bern, Dept Neurol, Inselspital, Bern, Switzerland

[8] Univ New South Wales Med, Ingham Inst Appl Med Res, Sydney, Australia

[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada

[10] Univ Vita Salute San Raffaele, Expt Neurophysiol Unit, Milan, Italy

[11] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, Ctr Neurosci Surg & Trauma, London, England

[12] Rigshosp, Dept Neurol, Danish MS Ctr, Copenhagen Univ Hosp, Glostrup, Denmark

[13] Univ Lille, INSERM, U1172, LilNCog,CHU Lille,FHU Precise, Lille, France

[14] Healthcare Business Merck KGaA, Darmstadt, Germany

[15] Cytel Inc, Geneva, Switzerland

[16] EMD Serono Inc, Billerica, MA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P008

引用

页码：21 / 22

页数：2

共 50 条

[41] Year-by-year lymphopenia rates in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5mg/kg in CLARITY and re-treated in CLARITY Extension
Cook, S.
Comi, G.
Giovannoni, G.
Rieckmann, P.
Soelberg-Sorensen, P.
Vermersch, P.
Dangond, F.
Hicking, C.
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 195 - 196
[42] Year 1 Performance of Adveva®, a Patient Support Program (PSP) for Patients Taking MAVENCLAD® (cladribine tablets) for Highly Active Relapsing Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK)
Morgan, Kate
Lott, Nadine
Lyons, Marco
NEUROLOGY, 2020, 94 (15)
[43] MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results
Reich, Daniel
Traboulsee, Anthony
Syed, Sana
Xu, Zhixing
Turner, Timothy
Arnold, Douglas
NEUROLOGY, 2023, 100 (17)
[44] MRI outcomes from the long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
Reich, D. S.
Traboulsee, A.
Syed, S.
Xu, Z.
Turner, T. J.
Arnold, D. L.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 334 - 335
[45] Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study
Selmaj, Krzysztof
Langdon, Dawn
Brochet, Bruno
Solari, Alessandra
Havrdova, Eva Kubala
Patti, Francesco
Piehl, Fredrik
Smyk, Andrzej
Lehn, Annette
Nolting, Axel
Montalban, Xavier
Lechner-Scott, Jeannette
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 655 - 657
[46] Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study
Baumstarck, K.
Pelletier, J.
Boucekine, M.
Auquier, P.
REVUE NEUROLOGIQUE, 2015, 171 (02) : 173 - 180
[47] Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis
Daniela Rau
Beate Müller
Susanne Übler
Advances in Therapy, 2023, 40 : 5547 - 5556
[48] Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis
Rau, Daniela
Mueller, Beate
Uebler, Susanne
ADVANCES IN THERAPY, 2023, 40 (12) : 5547 - 5556
[49] Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
Mark Gudesblatt
Karl Wissemann
Myassar Zarif
Barbara Bumstead
Lori Fafard
Jeffrey Wilken
Karen Blitz
Marijean Buhse
Sourav Santra
Christophe Hotermans
Lily Lee
CNS Drugs, 2018, 32 : 1173 - 1181
[50] EFFICACY OF CLADRIBINE TABLETS IN PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS: ANALYSIS OF POOLED DOUBLE-BLIND DATA FROM THE CLARITY AND ONWARD STUDIES
Giovannoni, Gavin
Montalban, Xavier
Rammohan, Kottil
Cook, Stuart
Comi, Giancarlo
Rieckmann, Peter
Soelberg-Sorensen, Per
Vermersch, Patrick
Dangond, Fernando
King, John
Damian, Doris
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E27 - E28

← 1 2 3 4 5 →